Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Managing antiphospholipid syndrome in pregnancy

    Research output: Contribution to journalReviewResearchpeer-review

  5. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Socioeconomic position and one-year mortality risk among patients with heart failure: A nationwide register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of diabetes among related and unrelated family members

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ischaemic heart disease, infection, and treatment of infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Diagnostic Potential of Intracardiac Echocardiography in Patients with Suspected Prosthetic Valve Endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION, MATERIALS AND METHODS: We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.

RESULTS: In total, 53,860 AF patients were included (VKA 37.7%, dabigatran 24.4%, rivaroxaban 16.9%, apixaban 21.0%). For standard dose dabigatran initiators, during almost all of the study period, the mean CHA2DS2-VASc and HAS-BLED scores were the lowest and decreased (2.6 and 2.2 in 2011 vs. 2.1 and 1.8 in 2016, respectively). Reduced dose apixaban initiators had rather stable mean CHA2DS2-VASc scores during the study period and the highest mean CHA2DS2-VASc score in 2016 (4.1). The mean HAS-BLED scores were similarly high among reduced dose apixaban and rivaroxaban initiators in years 2013-2016. From 2011 to 2014, a decrease in the frequency of prior stroke (p<0.001), age≥75years (p<0.001), and prior bleeding (p=0.007) was observed among dabigatran initiators. In the study period, apixaban initiators in general had the highest frequency of prior stroke and age≥75years.

CONCLUSIONS: Danish AF patients receiving standard dose dabigatran had the lowest and decreasing predicted stroke and bleeding risks during almost all study years. Patients receiving reduced dose apixaban had rather stable predicted risk of stroke during the study period and the highest mean CHA2DS2-VASc score in 2016.

Original languageEnglish
JournalThrombosis Research
Volume160
Pages (from-to)19-26
Number of pages8
ISSN0049-3848
DOIs
Publication statusPublished - Dec 2017

    Research areas

  • Journal Article

ID: 52410378